Screener
Axsome Therapeutics AXSM Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Accounts payable | 41,165 | 13,662 |
| Accrued expenses and other current liabilities | 17,229 | 818 |
| Operating lease liability | (608) | 208 |
| Net cash used in operating activities | (20,700) | (43,375) |
| Cash flows from investing activities | ||
| Purchases of equipment | (121) | (338) |
| Net cash used in investing activities | (121) | (338) |
| Cash flows from financing activities |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's operating cash flow?
- Axsome Therapeutics (AXSM) reported operating cash flow of -$20.7M in Q1 2026.
- How has Axsome Therapeutics's operating cash flow changed year-over-year?
- Axsome Therapeutics's operating cash flow increased by 52.3% year-over-year, from -$43.38M to -$20.7M.
- What is the long-term trend for Axsome Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Axsome Therapeutics's operating cash flow has grown at a -3.3% compound annual growth rate (CAGR), from -$108.23M to -$94.45M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Axsome Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude